Physician profile
Daniel Burke Karb
NPI 1619339470
$1,376.28
in general payments reported to CMS, 2019-2025
13 companies · $262 in 2025
The $262 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $112 · 2021: $17.66 · 2022: $499 · 2023: $217 · 2024: $98.64 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $577.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $248.87 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $228.43 | 2022-2023 | Ocaliva |
| Gilead Sciences, INC. | $206.87 | 2022 | |
| Janssen Biotech, INC. | $206.57 | 2021-2023 | Stelara |
| Ipsen Biopharmaceuticals, INC | $140.80 | 2025 | Iqirvo |
| Eisai INC. | $106.53 | 2025 | |
| Phathom Pharmaceuticals, INC. | $98.64 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.23 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.56 | 2020 | |
| Merck Sharp & Dohme LLC | $28.25 | 2019-2020 | |
| Celgene Corporation | $16.34 | 2022 | |
| Lilly USA, LLC | $14.55 | 2025 | Omvoh |
| Pfizer INC. | $12.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Karb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.